

Protocol

# Comparing the Effects of Oral Contraceptives Containing Levonorgestrel With Products Containing Antiandrogenic Progestins on Clinical, Hormonal, and Metabolic Parameters and Quality of Life in Women With Polycystic Ovary Syndrome: Crossover Randomized Controlled Trial Protocol

Mina Amiri<sup>1,2</sup>, PhD; Fatemeh Nahidi<sup>1</sup>, PhD; Davood Khalili<sup>3</sup>, MD, PhD; Razieh Bidhendi-Yarandi<sup>2,4</sup>, PhD; Fahimeh Ramezani Tehrani<sup>2</sup>, MD

<sup>1</sup>Department of Midwifery and Reproductive Health, Faculty of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran

<sup>2</sup>Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran

<sup>3</sup>Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Science, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran

<sup>4</sup>Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Islamic Republic Of Iran

**Corresponding Author:**

Fahimeh Ramezani Tehrani, MD  
Reproductive Endocrinology Research Center  
Research Institute for Endocrine Sciences  
Shahid Beheshti University of Medical Sciences  
24 Parvaneh, Yaman Street, Velenjak  
P.O. Box 19395-4763  
Tehran,  
Islamic Republic Of Iran  
Phone: 98 2243 2500  
Email: [ramezani@endocrine.ac.ir](mailto:ramezani@endocrine.ac.ir)

## Abstract

**Background:** Oral contraceptives (OCs) have been used as a first-line option for medical treatment in women with polycystic ovary syndrome (PCOS). Despite theoretical superiority of products containing antiandrogenic progestins compared to OCs containing levonorgestrel (LNG), the clinical advantage of these compounds remains unclear.

**Objective:** The aim of this study was to compare the effects of OCs containing LNG with products containing antiandrogenic progestins including cyproterone acetate, drospirenone, and desogestrel on clinical, hormonal, and metabolic parameters and quality of life in women with PCOS.

**Methods:** We conducted a 6-arm crossover randomized controlled trial with each arm including OCs containing LNG and one of those 3 OCs containing antiandrogenic progestins. The anthropometric and clinical manifestations and hormonal and biochemical parameters of participants were assessed at 6 time points including baseline, after washout period, and 3 and 6 months after intervention.

**Results:** The study is ongoing and follow-up of recruited women will continue until 2018.

**Conclusions:** This study will provide scientific evidence on comparability of OCs with the various progesterones that will assist in decision making taking into account cost effectiveness.

**Trial Registration:** Iranian Registry of Clinical Trials IRCT201702071281N2; <http://www.irct.ir/searchresult.php?keyword=&id=1281&number=2&pri=12869&total=10&m=1> (Archived by WebCite at <http://www.webcitation.org/6tSP8FNWo>)

(JMIR Res Protoc 2017;6(9):e191) doi: [10.2196/resprot.8631](https://doi.org/10.2196/resprot.8631)

**KEYWORDS**

polycystic ovary syndrome; oral contraceptives; randomized controlled trial; progestin

**Introduction**

Polycystic ovary syndrome (PCOS), the most common endocrine and metabolic disorder [1-3], which affects between 5% and 10% of reproductive age women [4,5], is characterized by chronic oligo-ovulation or anovulation and hyperandrogenism resulting in infertility, menstrual irregularities, hirsutism, acne, and alopecia [6,7]. PCOS is associated with an increased risk of metabolic disorders such as obesity, dyslipidemia, hyperinsulinemia, insulin resistance, and metabolic disturbances, which increase the risk of diabetes mellitus and cardiovascular disease [8-12]. Previous studies report that certain aspects of PCOS have negative effects on the health-related quality of life for these women [13,14].

Oral contraceptives (OCs) are frequently recommended as first-line medical treatment for the long-term management of menstrual disturbances and hyperandrogenism manifestations in women with PCOS who do not seek pregnancy [15-18]. The remedial effect of OCs is attributed to the suppression of pituitary gonadotropin secretion and a decrease in androgen secretion [19,20]; in addition, the estrogen component of these compounds increases circulating levels of sex hormone-binding globulin (SHBG), which decreases androgen bioavailability [1,21]. Moreover, the progestin component of some of the new generation of OCs inhibits 5 $\alpha$ -reductase activity and acts as an antagonist at the androgen receptor level [21,22], theoretically resulting in an increase in antiandrogenic activity [23]. Despite theoretical advantages of OCs with antiandrogenic properties from compounds such as cyproterone acetate (CA), drospirenone (DRSP), desogestrel (DSG), and ethinyl estradiol (EE) compared to OCs containing levonorgestrel (LNG) [1,24], clinical advantages of these compounds remain unclear [25].

In addition to the antiandrogenic effect of OCs, their metabolic effect is one of the main issues in OC therapy in patients with PCOS [26]. In fact, some studies have raised concerns regarding the potential adverse cardiovascular and metabolic effects of OCs in women with PCOS [2,27-30], including worsening insulin resistance and glucose tolerance and potential adverse effects on lipid patterns. It is also unclear whether the metabolic effects of OCs on PCOS are reduced by the use of certain progestin compounds. Despite the theoretical antiandrogenic advantage of the new generation of OCs, their possible metabolic adverse effects may be a serious threat [31].

Several studies that assessed the effectiveness of OCs on clinical, biochemical, and metabolic profiles in PCOS patients have reported conflicting findings [1,10,15,16,32-35]. However, a limited number of studies have compared the effects of the various OC products on different aspects of PCOS; the majority of these studies did not assess effects of OCs containing LNG.

Accordingly, in this crossover randomized controlled clinical trial, we aimed to compare the effects of OCs containing LNG

with products containing antiandrogenic progestins on the clinical, hormonal, and metabolic aspects and quality of life of reproductive-age women with PCOS.



We hypothesize that in PCOS patients, OCs containing antiandrogenic progestins including DRSP, CA, and DSG have no advantage over products containing LNG on the clinical, hormonal, and metabolic profiles of these women or on their quality of life.

**Methods****Overview of Study Design and Procedures**

This study is a single institution crossover randomized controlled clinical trial with 6 treatment groups (A, B, C, D, E, and F) that commenced in February 2016. Our study design was based on the Consolidated Standards of Reporting Trials (CONSORT) requirements [36]. The research team included a gynecologist, midwife, endocrinologist, epidemiologist, and statistician. The trial was conducted at the endocrinology clinic of the Research Institute for Endocrine Sciences (RIES) of the Shahid Beheshti University of Medical Sciences, Tehran, Iran. Figure 1 presents an overview of the study protocol. Participants were recruited through 4 primary sources: online through professional social networks and referrals from municipal health centers, private clinics, and the Tehran Lipid and Glucose Study (TLGS). The trial was conducted at an endocrine outpatient clinic.

Before entering the study, the purpose of the protocol was clearly explained to the patients and written informed consent was obtained from all women enrolled. All eligible patients were randomly assigned to treatment groups (Figure 2). Patients in each of the groups alternately received OCs containing LNG or a product containing antiandrogenic progestins including CA, DRSP, DSG, or EE for 6 months. There was a washout period of 6 to 8 weeks between the 2 treatments. Clinical, hormonal, metabolic, and quality of life assessments were assessed at the time of recruitment and again at follow-ups. Hence, each patient was assessed for clinical and biochemical measurements at 6 time points: before the first treatment (baseline 1), after taking the first treatment for 3 months, after taking the first treatment for 6 months, 6 to 8 weeks after stopping the first treatment (baseline 2), after taking the second treatment for 3 months, and after taking the second treatment for 6 months (see Table 1).

Baseline fasting (for at least 9 hours) blood samples were collected between days 3 and 5 of the spontaneous menstrual cycle or progesterone-induced menstrual bleeding. Follow-up visits for blood sampling and clinical assessment were performed at 3 to 7 days after using last tablet. All sera were stored at -80°C until the time of testing. Following completion of the study (samples and data collection), all data will be analyzed using Stata software (StataCorp LLC).

**Figure 1.** Overview of study design.**Figure 2.** Consolidated Standard of Reporting Trials flow diagram of the study.

## Ethical Considerations

Approval was obtained from the ethics committee of Shahid Beheshti University of Medical Sciences, Tehran, Iran (ethics code IR.SBMU.PHNM.1395.649). The trial is registered at the Iran Registry of Clinical Trials [IRCT201702071281N2].

Written informed consent was obtained from eligible participants after the content was clearly explained to the subjects by the trial assistant. All research tools, including questionnaires, will be completely anonymous; a unique code will, however, be included in each form in order to manage further references. All information on participants will be securely stored and only accessible to authenticated trial team members.

## Participants

Women with PCOS (age range 18 to 45 years) were recruited at the endocrine outpatient clinic of the RIES of the Shahid Beheshti University of Medical Sciences, Tehran, Iran, by publicly advertising in the community or by referral from physicians or other clinicians. PCOS was diagnosed according to the 2006 criteria from the Androgen Excess Society (AES) (hirsutism or hyperandrogenemia and oligo-ovulation/anovulation or polycystic ovaries with exclusion of other androgen excess or related disorders) [37]. Patients testing positive for secondary etiologies including hyperprolactinemia, thyroid dysfunction, Cushing syndrome, congenital adrenal hyperplasia, and virilizing tumors were excluded from the study. Inclusion criteria were normal fasting plasma glucose ( $<100$  mg/dL), normal cardiometabolic system, and normal hepatic function; all patients were nonsmokers and had negative pregnancy tests before enrollment. None of the women had taken medications known to affect plasma sex steroids for at least 3 months before the study. None of the patients planned to become pregnant or had had contraindications with the use of OCs.

Exclusion criteria were history of use of an exogenous hormonal agent within past 3 months; systemic disease such as cardiovascular disorder, renal disease, or liver disease; endocrinopathies including diabetes mellitus, thyroid dysfunction, hyperprolactinemia, and Cushing syndrome; contraindications to OCs; use of any medication related to PCOS such as hormonal, insulin sensitizer, or antiandrogen drugs within the previous 3 months; willingness for pregnancy; smoking; or any serious side effects of contraceptive use such as thrombosis, jaundice, or hepatic disorders. We excluded current study participants if they were unable to actively continue the cooperation required due to sickness, pregnancy, etc. Patients could terminate participation in the study for any reason. Patients who discontinued intervention for  $\geq 2$  months were excluded from the analyses.

## Interventions

In this study, patients were randomly assigned to treatment groups with interventions using different OC products:

- Group A: first treatment—EE 30  $\mu$ g + LNG 0.15 mg daily for 6 months; second treatment—EE 30  $\mu$ g + DRSP 3 mg daily for 6 months
- Group B: first treatment—EE 30  $\mu$ g + DRSP 3 mg daily for 6 months; second treatment—EE 30  $\mu$ g + LNG 0.15 mg daily for 6 months
- Group C: first treatment—EE 30  $\mu$ g + LNG 0.15 mg daily for 6 months; second treatment—EE 35  $\mu$ g + CA 2 mg daily for 6 months
- Group D: first treatment—EE 35  $\mu$ g + CA 2 mg daily for 6 months; second treatment—EE 30  $\mu$ g + LNG 0.15 mg daily for 6 months
- Group E: first treatment—EE 30  $\mu$ g + LNG 0.15 mg daily for 6 months; second treatment—EE 30  $\mu$ g + DSG 150  $\mu$ g daily for 6 months
- Group F: first treatment—EE 30  $\mu$ g + DSG 150  $\mu$ g daily for 6 months; second treatment—EE 30  $\mu$ g + LNG 0.15 mg daily for 6 months

All participants received EE 30  $\mu$ g + LNG 0.15 mg as the standard treatment. To eliminate carryover effect of treatments, a washout period of 6 to 8 weeks was in place between 2 treatments (Figure 2). Interventions were performed by a trained midwife with the assistance of another person who was aware of the type of intervention.

## Study Outcomes

Outcome measures were collected at 6 time points: before treatments, after washout period, and after 3 and 6 months of treatments (Table 1).

Only one person conducted clinical assessments of participants, and she was blinded to groups to minimize any assessor effects. Biochemical measurements were performed by an expert laboratory technician under the supervision of a laboratory sciences specialist.

In this trial, the primary outcomes were free androgen index (FAI) and homeostasis model assessment–insulin resistance (HOMA-IR). Secondary outcomes were modified Ferriman-Gallwey score (FG); acne; regularity of menstrual cycles; blood pressure; androgenic profiles including follicle-stimulating hormone (FSH), luteinizing hormone (LH), total testosterone (tT), SHBG, androstendione (A4), and dehydroepiandrosterone sulfate (DHEAS); metabolic profiles including fasting blood sugar (FBS) fasting insulin, HOMA-IR, triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C); and quality of life assessed by Health-Related Quality of Life Questionnaire for Polycystic Ovary Syndrome (PCOSQ-50) [13].

**Table 1.** Schedule of clinical and biochemical assessments.

Item	Baseline 1	At 3rd month of treatment	At 6th month of treatments	Baseline 2 (after washout period)	At 3rd month of treatment	At 6th month of treatment
<b>Demographic characteristics</b>	x					
Age, marital, educational, and occupational status						
<b>Menstrual history</b>						
Age of menarche	x					
Last menstrual period	x	x	x	x	x	x
Interval between menstrual cycles	x	x	x	x	x	x
Amenorrhea history	x					
<b>Medical and family history</b>						
Chief complaints (infertility, hirsutism, menstrual irregularity, acne, alopecia)	x					
Duration of PCOS <sup>a</sup> diagnosis	x					
History of previous treatments	x					
Hair removal methods	x	x	x	x	x	x
Past medical history	x					
Family history	x					
<b>Anthropometric and blood pressure measurements</b>						
Height	x					
Weight	x	x	x	x	x	x
Waist circumference	x	x	x	x	x	x
Hip circumference	x	x	x	x	x	x
Wrist circumference	x	x	x	x	x	x
Blood pressure	x	x	x	x	x	x
<b>Clinical hyperandrogenism symptom assessments</b>						
FG <sup>b</sup> score	x	x	x	x	x	x
Acne	x	x	x	x	x	x
Androgenic alopecia	x	x	x	x	x	x
<b>Laboratory assessments</b>						
Hormonal parameters (FSH <sup>c</sup> , LH <sup>d</sup> , tT <sup>e</sup> , FAI <sup>f</sup> , SHBG <sup>g</sup> , A4 <sup>h</sup> , DHEAS <sup>i</sup> )	x	x	x	x	x	x
Metabolic parameters (FBS <sup>j</sup> , fasting insulin, HOMA-IR <sup>k</sup> , TG <sup>l</sup> , TC <sup>m</sup> , LDL-C <sup>n</sup> , HDL-C <sup>o</sup> )	x	x	x	x	x	x
Quality of life	x	x	x	x	x	x
Ultrasound assessment	x					

<sup>a</sup>PCOS: polycystic ovary syndrome.<sup>b</sup>FG: Ferriman-Gallwey score.<sup>c</sup>FSH: follicle-stimulating hormone.<sup>d</sup>LH: luteinizing hormone.<sup>e</sup>tT: total testosterone.<sup>f</sup>FAI: free androgen index.<sup>g</sup>SHBG: sex hormone-binding globulin.



<sup>h</sup>A4: androstenedione.

<sup>i</sup>DHEAS: dehydroepiandrosterone sulfate.

<sup>j</sup>FBS: fasting blood sugar.

<sup>k</sup>HOMA-IR: homeostatic model assessment–insulin resistance.

<sup>l</sup>TG: triglycerides.

<sup>m</sup>TC: total cholesterol.

<sup>n</sup>LDL-C: low-density lipoprotein cholesterol.

<sup>o</sup>HDL-C: high-density lipoprotein cholesterol.

## Clinical Assessment

In this study, a single trained midwife in the endocrinology clinic under supervision of a reproductive endocrinologist assessed the anthropometric parameters, menstrual cycles, hirsutism, acne, alopecia, and acanthosis nigricans in participants at baselines and follow-ups. She was blinded to type of treatment.

Patient weights were measured when they were minimally clothed using a digital scale (Seca 707, Seca GmbH) and rounded to the nearest 100 grams. Height was measured without shoes in the standing position with shoulders in normal alignment using a tape measure. Waist circumference was measured with an unstretched tape measure at the level of umbilicus without any pressure to the body surface and recorded to the nearest 0.1 cm. Hip circumference was measured at the level of anterior superior iliac spine without any pressure to the body surface. Wrist circumference was measured similarly. Body mass index was calculated as weight in kilograms (kg) divided by height squared ( $m^2$ ). Systolic and diastolic blood pressure were measured twice on the right arm with the patient in a seated position by a qualified midwife with a standard mercury sphygmomanometer after the subject sat for 15 minutes; the mean of these 2 measurements was recorded.

All patients were evaluated for regularity of menstrual cycles. Those who had intervals of menstrual cycle more than 35 days were diagnosed as having oligomenorrhea, less than 22 days as polymenorrhea, and those with absence of menstrual periods for 6 months or longer as amenorrhea [37,38]. Spotting was assessed and registered.

In this study, the FG score was used for determining the density of terminal hair at 9 different body sites: upper lip, chin, chest, upper back, lower back, upper abdomen, lower abdomen, arm, and thigh; this scoring system grades excess terminal body or facial hair growth based on a scale of 0 (absence of terminal hairs) to 4 (frank virilization), and a total score of 8 or more is considered as hirsutism [39,40]. Participants were asked to refrain from shaving or using other depilatory methods in the month before evaluation to improve accuracy of assessment.

The severity of acne was classified according to a grading system based on the number of lesions and their spread on the face, back, and chest: mild—comedones (clogged hair follicles often similar to pustules that do not have any inflammation)

present; moderate—the number of erythematous and popular moderate lesions was from 10 to 40 or number of pustules was from 10 to 40 (especially on the face); moderate to severe—the number of multiple and numerous papules and pustules was from 40 to 100 often accompanied by comedones in numbers of 40 to 100 on the face, upper chest, and back; severe—nodulocystic acne with painful nodules or pustules frequently observed on the chest and face and accompanied by smaller papules, pustules, and comedones [41].

To diagnose androgenic alopecia in participants, we used the following classification, which was presented by Ludwig [42] in Germany:

- Grade I: perceptible thinning of the hair on the crown limited in the front by a line situated 1 to 3 cm behind the frontal hair line
- Grade II: pronounced rarefaction of the hair on the crown within the area seen in Grade I
- Grade III: complete baldness (total denudation) within the area seen in Grades I and II

In addition, we will assess the common side effects of OCs during and after follow-ups (Table 2).

## Hormonal Assay

FSH and LH will be measured by immunoradimetric assay (IRMA) (Institute of Isotopes Co Ltd) using the Wallac Wizard gamma counter (GMI Inc); tT, A4, and DHEAS will be measured by enzyme immunoassay (EIA) (Diagnostics Biochem Canada Inc). SHBG will be measured by immunoenzymometric assay (IEMA) (Mercodia AB); all enzyme-linked immunosorbent assay (ELISA) tests were performed using the Sunrise ELISA reader (Tecan Trading AG); and FAI will be calculated using the formula  $[tT(nmol/L) \times 100 / SHBG(nmol/L)]$ .

Biochemical hyperandrogenemia will be identified if FAI, DHEAS, or A4 levels are in the upper 95th percentile ( $tT=0.89$  ng/mL,  $A4=2.9$  ng/mL,  $DHEAS=179$   $\mu g/dL$ ,  $FAI=5.39$ ) considering the women studied were not on any hormonal medication and had no clinical evidence of hyperandrogenism and menstrual dysfunction. Hyperandrogenism was determined as clinical hyperandrogenism and/or biochemical hyperandrogenemia [43].

Inter- and intra-assay coefficients of variation for all hormonal measurements will be defined.

**Table 2.** A comparison of the common side effects of oral contraceptives in polycystic ovary syndrome patients.

Side effects	Type of treatment			
	OC <sup>a</sup> containing LNG <sup>b</sup>	OC containing CA <sup>c</sup>	OC containing DRSP <sup>d</sup>	OC containing DSG <sup>e</sup>
Headache	x	x	x	x
Dizziness	x	x	x	x
Nausea	x	x	x	x
Vomiting	x	x	x	x
Breast pain/tenderness	x	x	x	x
Spotting	x	x	x	x

<sup>a</sup>OC: oral contraceptive.<sup>b</sup>LNG: levonorgestrel.<sup>c</sup>CA: cyproterone.<sup>d</sup>DRSP: drospirenone.<sup>e</sup>DSG: desogestrel.

## Metabolic Assessment

FBS will be measured using the glucose oxidase method (Pars Azmun Co). HOMA-IR will be calculated using electrochemiluminescent immunoassay (ECLIA). Normal range of HOMA-IR is determined in the Iranian population by using ECLIA method with a cut-off of 2.63 [44]. TG levels will be measured using the enzymatic colorimetric method with glycerol phosphate oxidase (Pars Azmun Co). TC level will be determined using enzymatic colorimetric method with cholesterol esterase and cholesterol oxidase (Pars Azmun Co). Level of HDL-C will be determined after precipitation of apolipoprotein  $\beta$  with phosphotungstic acid and enzymatic colorimetric method (Pars Azmun Co). LDL-C level will be calculated using enzymatic colorimetric method (Pars Azmun Co) [45]. Serum insulin concentration will be measured using ECLIA method (Roche Diagnostics) [46]. Albumin will be measured using the enzymatic colorimetric method with cholesterol esterase and cholesterol oxidase (Pars Azmun Co). Inter- and intra-assay coefficients of variation for all metabolic measurement will be defined.

## Ultrasound Assessment

Ultrasound examination of the uterus and ovaries was performed using a 6-MHz transvaginal transducer or a 4-MHz transabdominal transducer in cases where sociocultural constraints precluded a vaginal approach for ultrasonography. Sonography was performed at the first baseline visit when the blood samples were collected. Endometrial thickness, ovarian volume, number, diameter, and distribution of the follicles were recorded. The ovaries were considered as polycystic when observed as having increased ovarian size and/or at least 10 follicular cysts measuring 2 to 9 mm [47].

## Quality of Life Assessment

The PCOSQ-50, developed by Nasiri-Amiri et al [13], was used to evaluate the quality of life of recruited participants. This questionnaire includes 50 items in the following 6 domains:

psychosocial and emotional, fertility, sexual function, obesity and menstrual disorders, and coping. Items were scored based on the 5-point Likert scale.

## Sample Size

To show that the OCs containing LNG are clinically as effective as those containing antiandrogenic progestins including DRSP, CA, EE, and DSG, we used a noninferiority hypothesis as seen in Figure 3, where  $\mu_T$  is the mean of the test drug,  $\mu_S$  is the mean of standard therapy, and  $\delta$  is a difference of clinical importance. By rejecting the null hypothesis, we conclude that the difference between the test drug and the standard therapy is less than a clinically meaningful difference (ie,  $\delta$ ), and therefore the test drug is as effective as the standard therapy [48].

We considered 80% power, 0.05 type I error, and  $=0.52$ , where  $\delta$  is defined as the difference of mean of test drug and standard therapy minus difference of clinical importance divided by standard deviation, as seen in Figure 4. Sample size was calculated from the table introduced by sample size calculations in clinical research, as seen in Figure 5 [49].

We estimated 25 samples were needed for each group, with 150 total samples needed. Considering 25% withdrawal, we will need 200 cases.

## Randomization and Blinding

A blocking or stratification random allocation with a block size of 6 using a computer-based random number generator was prepared to assign participants to treatment groups. The randomization sequence was prepared before the trial, initiated by an independent statistician. For those patients meeting the inclusion criteria and providing informed consent, the research assistant assigned the next randomization sequence according to the schedule. Although participants couldn't be blinded to treatment type because the artifact was obvious, both clinical examiner and data analyst were blinded to participant groups during the trial.

**Figure 3.** Noninferiority hypothesis.

$$\begin{cases} H_0 : \mu_S - \mu_T \geq \delta \\ H_a : \mu_S - \mu_T < \delta \end{cases}$$

**Figure 4.** Standardized difference of observational and clinical mean difference.

$$\theta = (\epsilon - \delta) / \sigma, \epsilon = \mu_S - \mu_T$$

**Figure 5.** Sample size formula.

$$n = \frac{(z\alpha + z\beta)^2 \sigma^2}{(\epsilon - \delta)^2}$$

## Statistical Analysis

Descriptive statistics will be reported appropriately; normality assumptions will be tested per case by Kolmogorov-Smirnov or Shapiro-Wilk tests. A crossover study is a longitudinal study type in which participants receive treatments in different phases. Therefore, we will use repeated measures which are correlated. We will use statistical analysis appropriate for correlated measures such as generalized estimated equations or repeated-measurement designs to find the differences between treatments. This will be done after finishing the second phase. In addition, in first phase of study, we will estimate between-group differences using generalized linear models. A washout period was taken into account although carryover effect (residual effect) will be tested at the beginning of the analysis via appropriate statistical tests like *t* tests presented by Fleiss [50]. Statistical analysis will be performed using the software package Stata version 12 (StataCorp LLC).

## Results

This trial began enrollment in February 2016, and 200 participants are currently enrolled as planned. Recruitment of participants and follow-ups are still ongoing, and preliminary results are expected to be published in 2018.

## Discussion

This study presents a protocol for a crossover randomized controlled trial to compare the effects of OCs containing LNG with products containing antiandrogenic progestins including CA, DRSP, EE, and DSG on clinical, hormonal, and metabolic findings and quality of life of reproductive-age women with PCOS. To our knowledge, this is the first trial with crossover design to compare the effects of different OCs on various clinical and biochemical aspects of PCOS. Results of this study will empower clinicians with evidence-based recommendations regarding treatment options and follow-up duration.

Different approaches have been used to treat patients with PCOS. Use of OCs is one of the most common treatment options for improving clinical and biochemical findings of PCOS [21,51]. It is well known that improvement in clinical signs of PCOS usually begins after 3 to 6 months of therapy, but because hair follicles have a half-life of up to 6 months, lifelong therapy

may be needed to prevent recurrence [16,52]. In this study, patients were treated with OCs for a 6-month period in each phase.

To minimize selection bias, we enrolled patients from different settings such as professional social networks and municipal health centers, private clinics, and from among participants of the TLGS. These settings were located in different districts of Tehran. All patients who met the eligibility criteria were included in the study. Adolescent and premenopausal patients were not included in the trial because of different clinical and hormonal statuses in these periods.

An important strength of this study is its crossover design, in which the interventions under investigation are evaluated within the same patients, eliminating between-subject variability [53]. We designed this study and its methodological issues such as allocation, blinding, flow diagrams, patient preference, and carryover effects based on guidelines reported in the CONSORT statement [36]. This clinical trial is a head-to-head trial that permits patients to receive multiple treatments; hence, it can express preferences for or against particular treatments.

This study has limitations. Patients may drop out after the first intervention period and not receive a second treatment. This makes within-subject comparison impossible and is particularly important if withdrawal is related to side effects. We expect a considerable rate of loss to follow-up. To eliminate carryover effects, a washout period of 6 to 8 weeks was scheduled between treatments. Considering carryover effects of treatments across study periods can potentially distort the results obtained during the second treatment and the observed treatment effects will depend upon the order in which they will be received, hence we designed 6 treatment arms with different treatment orders. We intend to assess side effects of treatments. Considering our patients were diagnosed by AES criteria, our results may not be generalizable for those minor phenotypes diagnosed using Rotterdam criteria.

Finally, it is important to note that this project and its design are novel in the management of PCOS. If OCs containing LNG are as effective as OCs containing CA, DRSP, EE, or DSG without safety concerns, they may be recommended as a cost-effective first-line treatment for patients who suffer from the symptoms of PCOS. Therefore, we predict that the findings of this clinical trial will provide useful information for clinicians.



## Acknowledgments

This manuscript, a part of a PhD thesis of Mina Amiri, was supported by a research grant from the Research Institute for Endocrine Sciences, Reproductive Endocrinology Research Center, Shahid Beheshti University of Medical Science, Tehran, Iran. The authors would like to express their gratitude to the patients participating in the study. They would also like to acknowledge Ms Niloofar Shiva for critical editing of the English grammar and syntax in the manuscript.

## Authors' Contributions

MA was involved in the study conception and design and data collection, carried out the sample analysis and interpretation of data, and drafted the manuscript. FRT was involved in the study conception and design and carried out the analysis and interpretation of data, managed the literature search, and drafted the manuscript. FN participated in the study conception and design, carried out the analysis and interpretation of data, drafted the manuscript, and wrote critical revisions. DK participated in the study design and analysis and helped to draft the manuscript. RB participated in statistical analyses and randomization design. MT will contribute to interpreting laboratory tests. All authors have read and approved the final manuscript.

## Conflicts of Interest

None declared.

## References

1. De Leo V, Di Sabatino A, Musacchio MC, Morgante G, Sclaro V, Cianci A, et al. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome. *Contraception*. Sep 2010;82(3):276-280. [doi: [10.1016/j.contraception.2010.04.002](https://doi.org/10.1016/j.contraception.2010.04.002)] [Medline: [20705157](https://pubmed.ncbi.nlm.nih.gov/20705157/)]
2. Gul OB, Somunkiran A, Yucel O, Demirci F, Ozdemir I. The effect of ethinyl estradiol-cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome. *Arch Gynecol Obstet*. Jan 2008;277(1):25-30. [doi: [10.1007/s00404-007-0401-x](https://doi.org/10.1007/s00404-007-0401-x)] [Medline: [17618446](https://pubmed.ncbi.nlm.nih.gov/17618446/)]
3. Orio F, Vuolo L, Palomba S, Lombardi G, Colao A. Metabolic and cardiovascular consequences of polycystic ovary syndrome. *Minerva Ginecol*. Feb 2008;60(1):39-51. [Medline: [18277351](https://pubmed.ncbi.nlm.nih.gov/18277351/)]
4. Ehrmann DA. Polycystic ovary syndrome. *N Engl J Med*. Mar 24, 2005;352(12):1223-1236. [doi: [10.1056/NEJMra041536](https://doi.org/10.1056/NEJMra041536)] [Medline: [15788499](https://pubmed.ncbi.nlm.nih.gov/15788499/)]
5. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. *J Clin Endocrinol Metab*. Jun 2004;89(6):2745-2749. [doi: [10.1210/jc.2003-032046](https://doi.org/10.1210/jc.2003-032046)] [Medline: [15181052](https://pubmed.ncbi.nlm.nih.gov/15181052/)]
6. Kahraman K, Sükür YE, Atabekoğlu CS, Ateş C, Taşkın S, Cetinkaya SE, et al. Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial. *Arch Gynecol Obstet*. Aug 2014;290(2):321-328. [doi: [10.1007/s00404-014-3217-5](https://doi.org/10.1007/s00404-014-3217-5)] [Medline: [24676694](https://pubmed.ncbi.nlm.nih.gov/24676694/)]
7. Amiri M, Ramezani TF, Nahidi F, Bidhendi YR, Behboudi-Gandevani S, Azizi F. Association between biochemical hyperandrogenism parameters and Ferriman-Gallwey score in patients with polycystic ovary syndrome: a systematic review and meta-regression analysis. *Clin Endocrinol (Oxf)*. Sep 2017;87(3):217-230. [doi: [10.1111/cen.13389](https://doi.org/10.1111/cen.13389)] [Medline: [28575537](https://pubmed.ncbi.nlm.nih.gov/28575537/)]
8. Dunaif A. Polycystic ovary syndrome in 2011: genes, aging and sleep apnea in polycystic ovary syndrome. *Nat Rev Endocrinol*. Dec 20, 2011;8(2):72-74. [doi: [10.1038/nrendo.2011.227](https://doi.org/10.1038/nrendo.2011.227)] [Medline: [22183129](https://pubmed.ncbi.nlm.nih.gov/22183129/)]
9. Robinson S, Henderson AD, Gelding SV, Kiddy D, Niththyananthan R, Bush A, et al. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. *Clin Endocrinol (Oxf)*. Mar 1996;44(3):277-284. [Medline: [8729522](https://pubmed.ncbi.nlm.nih.gov/8729522/)]
10. Aydin K, Cinar N, Aksoy DY, Bozdag G, Yildiz BO. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination. *Contraception*. Mar 2013;87(3):358-362. [doi: [10.1016/j.contraception.2012.07.005](https://doi.org/10.1016/j.contraception.2012.07.005)] [Medline: [22898361](https://pubmed.ncbi.nlm.nih.gov/22898361/)]
11. Amiri M, Ramezani TF, Nahidi F, Kabir A, Azizi F, Carmina E. Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: a meta-analysis comparing products containing cyproterone acetate with third generation progestins. *Metabolism*. Aug 2017;73:22-35. [doi: [10.1016/j.metabol.2017.05.001](https://doi.org/10.1016/j.metabol.2017.05.001)] [Medline: [28732568](https://pubmed.ncbi.nlm.nih.gov/28732568/)]
12. Amiri M, Ramezani TP, Ramezani TF. Effect of interventions based on lifestyle modification on clinical, hormonal and metabolic findings in the patients with polycystic ovary syndrome: a systematic review. *Iran J Endocrinol Metab*. Feb 2016;17(6):489-500. [FREE Full text]
13. Nasiri-Amiri F, Ramezani TF, Simbar M, Montazeri A, Mohammadpour RA. Health-related quality of life questionnaire for polycystic ovary syndrome (PCOSQ-50): development and psychometric properties. *Qual Life Res*. Dec 2016;25(7):1791-1801. [doi: [10.1007/s11136-016-1232-7](https://doi.org/10.1007/s11136-016-1232-7)] [Medline: [26814480](https://pubmed.ncbi.nlm.nih.gov/26814480/)]
14. Hahn S, Janssen OE, Tan S, Pleger K, Mann K, Schedlowski M, et al. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. *Eur J Endocrinol*. Dec 2005;153(6):853-860. [FREE Full text] [doi: [10.1530/eje.1.02024](https://doi.org/10.1530/eje.1.02024)] [Medline: [16322391](https://pubmed.ncbi.nlm.nih.gov/16322391/)]

15. Cagnacci A, Paoletti AM, Renzi A, Orrù M, Pilloni M, Melis GB, et al. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. *J Clin Endocrinol Metab.* Aug 2003;88(8):3621-3625. [doi: [10.1210/jc.2003-030328](https://doi.org/10.1210/jc.2003-030328)] [Medline: [12915645](https://pubmed.ncbi.nlm.nih.gov/12915645/)]
16. Kriplani A, Periyasamy AJ, Agarwal N, Kulshrestha V, Kumar A, Ammini AC. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. *Contraception.* Aug 2010;82(2):139-146. [doi: [10.1016/j.contraception.2010.02.009](https://doi.org/10.1016/j.contraception.2010.02.009)] [Medline: [20654754](https://pubmed.ncbi.nlm.nih.gov/20654754/)]
17. Ozdemir S, Gökemli H, Gezginç K, Ozdemir M, Kiyici A. Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome. *Int J Gynaecol Obstet.* Oct 2008;103(1):44-49. [doi: [10.1016/j.ijgo.2008.05.017](https://doi.org/10.1016/j.ijgo.2008.05.017)] [Medline: [18635183](https://pubmed.ncbi.nlm.nih.gov/18635183/)]
18. Uras R, Orrù M, Pani F, Marotto MF, Pilloni M, Guerriero S, et al. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome. *Contraception.* Aug 2010;82(2):131-138. [doi: [10.1016/j.contraception.2010.01.022](https://doi.org/10.1016/j.contraception.2010.01.022)] [Medline: [20654753](https://pubmed.ncbi.nlm.nih.gov/20654753/)]
19. Romualdi D, De Cicco S, Busacca M, Gagliano D, Lanzzone A, Guido M. Clinical efficacy and metabolic impact of two different dosages of ethinyl-estradiol in association with drospirenone in normal-weight women with polycystic ovary syndrome: a randomized study. *J Endocrinol Invest.* Sep 2013;36(8):636-641. [doi: [10.1007/BF03346756](https://doi.org/10.1007/BF03346756)] [Medline: [24105072](https://pubmed.ncbi.nlm.nih.gov/24105072/)]
20. Pehlivanov B, Mitkov M. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome. *Eur J Contracept Reprod Health Care.* Mar 2007;12(1):30-35. [doi: [10.1080/13625180600983082](https://doi.org/10.1080/13625180600983082)] [Medline: [17455042](https://pubmed.ncbi.nlm.nih.gov/17455042/)]
21. Vrbíková J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. *Hum Reprod Update.* 2005;11(3):277-291. [doi: [10.1093/humupd/dmi005](https://doi.org/10.1093/humupd/dmi005)] [Medline: [15790599](https://pubmed.ncbi.nlm.nih.gov/15790599/)]
22. Hillard PJA. Oral contraceptives and the management of hyperandrogenism-polycystic ovary syndrome in adolescents. *Endocrinol Metab Clin North Am.* Sep 2005;34(3):707-723. [doi: [10.1016/j.ecl.2005.04.012](https://doi.org/10.1016/j.ecl.2005.04.012)] [Medline: [16085167](https://pubmed.ncbi.nlm.nih.gov/16085167/)]
23. Mathur R, Levin O, Azziz R. Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome. *Ther Clin Risk Manag.* Apr 2008;4(2):487-492. [FREE Full text] [Medline: [18728832](https://pubmed.ncbi.nlm.nih.gov/18728832/)]
24. Glintborg D, Sidelmann JJ, Altinok ML, Mumm H, Andersen M. Increased thrombin generation in women with polycystic ovary syndrome: a pilot study on the effect of metformin and oral contraceptives. *Metabolism.* Oct 2015;64(10):1272-1278. [doi: [10.1016/j.metabol.2015.06.011](https://doi.org/10.1016/j.metabol.2015.06.011)] [Medline: [26194691](https://pubmed.ncbi.nlm.nih.gov/26194691/)]
25. Yildiz BO. Approach to the patient: contraception in women with polycystic ovary syndrome. *J Clin Endocrinol Metab.* Mar 2015;100(3):794-802. [doi: [10.1210/jc.2014-3196](https://doi.org/10.1210/jc.2014-3196)] [Medline: [25701301](https://pubmed.ncbi.nlm.nih.gov/25701301/)]
26. Diamanti-Kandarakis E, Baillargeon J, Luorno MJ, Jakubowicz DJ, Nestler JE. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. *J Clin Endocrinol Metab.* May 2003;88(5):1927-1932. [doi: [10.1210/jc.2002-021528](https://doi.org/10.1210/jc.2002-021528)] [Medline: [12727935](https://pubmed.ncbi.nlm.nih.gov/12727935/)]
27. Mastorakos G, Koliopoulos C, Deligeoroglou E, Diamanti-Kandarakis E, Creatsas G. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. *Fertil Steril.* Feb 2006;85(2):420-427. [doi: [10.1016/j.fertnstert.2005.07.1306](https://doi.org/10.1016/j.fertnstert.2005.07.1306)] [Medline: [16595221](https://pubmed.ncbi.nlm.nih.gov/16595221/)]
28. Carmina E. Oral contraceptives and cardiovascular risk in women with polycystic ovary syndrome. *J Endocrinol Invest.* May 2013;36(5):358-363. [doi: [10.3275/8882](https://doi.org/10.3275/8882)] [Medline: [23449010](https://pubmed.ncbi.nlm.nih.gov/23449010/)]
29. Sitruk-Ware R. Pharmacological profile of progestins. *Maturitas.* Apr 15, 2004;47(4):277-283. [doi: [10.1016/j.maturitas.2004.01.001](https://doi.org/10.1016/j.maturitas.2004.01.001)] [Medline: [15063480](https://pubmed.ncbi.nlm.nih.gov/15063480/)]
30. Falsetti L, Gambera A, Tisi G. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome. *Hum Reprod.* Jan 2001;16(1):36-42. [Medline: [11139533](https://pubmed.ncbi.nlm.nih.gov/11139533/)]
31. Taheripanah R, Sepahvandi M, Entezari A, Amiri Z, Samani EN. Evaluation of serum PSA after cyproterone compound treatment compared with oral contraceptive pill in hirsute polycystic ovary syndrome patients. *Middle East Fertility Society Journal.* Jul 2010;15(3):159-162. [doi: [10.1016/j.mefs.2010.06.007](https://doi.org/10.1016/j.mefs.2010.06.007)]
32. Karabulut A, Demirlenk S, Sevkett O. Effects of ethinyl estradiol-cyproterone acetate treatment on metabolic syndrome, fat distribution and carotid intima media thickness in polycystic ovary syndrome. *Gynecol Endocrinol.* Apr 2012;28(4):245-248. [doi: [10.3109/09513590.2011.613971](https://doi.org/10.3109/09513590.2011.613971)] [Medline: [21961995](https://pubmed.ncbi.nlm.nih.gov/21961995/)]
33. Bhattacharya SM, Jha A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. *Fertil Steril.* Oct 2012;98(4):1053-1059. [doi: [10.1016/j.fertnstert.2012.06.035](https://doi.org/10.1016/j.fertnstert.2012.06.035)] [Medline: [22795636](https://pubmed.ncbi.nlm.nih.gov/22795636/)]
34. Yildizhan R, Gokce AI, Yildizhan B, Cim N. Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up. *Gynecol Endocrinol.* May 2015;31(5):396-400. [doi: [10.3109/09513590.2015.1006187](https://doi.org/10.3109/09513590.2015.1006187)] [Medline: [25739031](https://pubmed.ncbi.nlm.nih.gov/25739031/)]
35. Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. *J Clin Endocrinol Metab.* Jun 2004;89(6):2817-2823. [doi: [10.1210/jc.2003-031158](https://doi.org/10.1210/jc.2003-031158)] [Medline: [15181063](https://pubmed.ncbi.nlm.nih.gov/15181063/)]

36. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMC Med.* 2010;8:18. [FREE Full text] [doi: [10.1186/1741-7015-8-18](https://doi.org/10.1186/1741-7015-8-18)] [Medline: [20334633](https://pubmed.ncbi.nlm.nih.gov/20334633/)]
37. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. *J Clin Endocrinol Metab.* Nov 2006;91(11):4237-4245. [doi: [10.1210/jc.2006-0178](https://doi.org/10.1210/jc.2006-0178)] [Medline: [16940456](https://pubmed.ncbi.nlm.nih.gov/16940456/)]
38. Laven JSE, Imani B, Eijkemans MJC, Fauser BCJM. New approach to polycystic ovary syndrome and other forms of anovulatory infertility. *Obstet Gynecol Surv.* Nov 2002;57(11):755-767. [doi: [10.1097/01.OGX.0000035710.90684.24](https://doi.org/10.1097/01.OGX.0000035710.90684.24)] [Medline: [12447098](https://pubmed.ncbi.nlm.nih.gov/12447098/)]
39. Goodman NF, Bledsoe MB, Cobin RH, Futterweit W, Goldzieher JW, Petak SM, et al. American Association of Clinical Endocrinologists Hyperandrogenic Disorders Task Force. American Association of Clinical Endocrinologists medical guidelines for the clinical practice for the diagnosis and treatment of hyperandrogenic disorders. *Endocr Pract.* 2001;7(2):120-134. [Medline: [12940239](https://pubmed.ncbi.nlm.nih.gov/12940239/)]
40. Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. *Hum Reprod Update.* 2012;18(2):146-170. [doi: [10.1093/humupd/dmr042](https://doi.org/10.1093/humupd/dmr042)] [Medline: [22064667](https://pubmed.ncbi.nlm.nih.gov/22064667/)]
41. Wang X, Wang H, Zhang L, Guo M, Huang Z. Topical ALA PDT for the treatment of severe acne vulgaris. *Photodiagnosis Photodyn Ther.* Mar 2010;7(1):33-38. [doi: [10.1016/j.pdpdt.2010.01.003](https://doi.org/10.1016/j.pdpdt.2010.01.003)] [Medline: [20230991](https://pubmed.ncbi.nlm.nih.gov/20230991/)]
42. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. *Br J Dermatol.* Sep 1977;97(3):247-254. [Medline: [921894](https://pubmed.ncbi.nlm.nih.gov/921894/)]
43. Tehrani FR, Rashidi H, Azizi F. The prevalence of idiopathic hirsutism and polycystic ovary syndrome in the Tehran Lipid and Glucose Study. *Reprod Biol Endocrinol.* Nov 01, 2011;9:144. [FREE Full text] [doi: [10.1186/1477-7827-9-144](https://doi.org/10.1186/1477-7827-9-144)] [Medline: [22044512](https://pubmed.ncbi.nlm.nih.gov/22044512/)]
44. Zadeh-Vakili A, Tehrani FR, Hosseini-panah F. Waist circumference and insulin resistance: a community based cross sectional study on reproductive aged Iranian women. *Diabetol Metab Syndr.* Aug 10, 2011;3:18. [FREE Full text] [doi: [10.1186/1758-5996-3-18](https://doi.org/10.1186/1758-5996-3-18)] [Medline: [21831271](https://pubmed.ncbi.nlm.nih.gov/21831271/)]
45. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem.* Jun 1972;18(6):499-502. [FREE Full text] [Medline: [4337382](https://pubmed.ncbi.nlm.nih.gov/4337382/)]
46. Ramezani TF, Montazeri SA, Hosseini-panah F, Cheraghi L, Erfani H, Tohidi M, et al. Trend of cardio-metabolic risk factors in polycystic ovary syndrome: a population-based prospective cohort study. *PLoS One.* 2015;10(9):e0137609. [FREE Full text] [doi: [10.1371/journal.pone.0137609](https://doi.org/10.1371/journal.pone.0137609)] [Medline: [26360602](https://pubmed.ncbi.nlm.nih.gov/26360602/)]
47. Battaglia C, Artini PG, Salvatori M, Giulini S, Petraglia F, Maxia N, et al. Ultrasonographic patterns of polycystic ovaries: color Doppler and hormonal correlations. *Ultrasound Obstet Gynecol.* May 1998;11(5):332-336. [FREE Full text] [doi: [10.1046/j.1469-0705.1998.11050332.x](https://doi.org/10.1046/j.1469-0705.1998.11050332.x)] [Medline: [9644772](https://pubmed.ncbi.nlm.nih.gov/9644772/)]
48. Blackwelder WC. "Proving the null hypothesis" in clinical trials. *Control Clin Trials.* Dec 1982;3(4):345-353. [Medline: [7160191](https://pubmed.ncbi.nlm.nih.gov/7160191/)]
49. O'Brien C. Sample size calculations in clinical research, second edition, by Shein-Chung Chow, Jun Shao, Hansheng Wang. *Int Stat Rev.* 2008;76(2):301-302. [doi: [10.1111/j.1751-5823.2008.00054.3.x](https://doi.org/10.1111/j.1751-5823.2008.00054.3.x)]
50. Fleiss J. The Design and Analysis of Clinical Experiments. New York. Wiley; 1999.
51. Helvacı N, Yildiz BO. Oral contraceptives in polycystic ovary syndrome. *Minerva Endocrinol.* Sep 2014;39(3):175-187. [Medline: [25003228](https://pubmed.ncbi.nlm.nih.gov/25003228/)]
52. Hohl A, Ronsoni MF, Oliveira MD. Hirsutism: diagnosis and treatment. *Arq Bras Endocrinol Metabol.* Mar 2014;58(2):97-107. [FREE Full text] [Medline: [24830586](https://pubmed.ncbi.nlm.nih.gov/24830586/)]
53. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. *Am J Epidemiol.* Jan 15, 1991;133(2):144-153. [Medline: [1985444](https://pubmed.ncbi.nlm.nih.gov/1985444/)]

## Abbreviations

- A4:** androstenedione  
**AES:** Androgen Excess Society  
**CA:** cyproterone  
**CONSORT:** Consolidated Standards of Reporting Trials  
**DHEAS:** dehydroepiandrosterone sulfate  
**DRSP:** drospirenone  
**DSG:** desogestrel  
**ECLIA:** electrochemiluminescent immunoassay  
**EE:** ethinyl estradiol  
**EIA:** enzyme immunoassay  
**ELISA:** enzyme-linked immunosorbent assay

**FAI:** free androgen index  
**FBS:** fasting blood sugar  
**FG:** Ferriman-Gallwey score  
**FSH:** follicle-stimulating hormone  
**HDL-C:** high-density lipoprotein cholesterol  
**HOMA-IR:** homeostatic model assessment–insulin resistance  
**IEMA:** immunoenzymometric assay  
**IRMA:** immunoradimetric assay  
**LDL-C:** low-density lipoprotein cholesterol  
**LH:** luteinizing hormone  
**LNG:** levonorgestrel  
**OC:** oral contraceptive  
**PCOS:** polycystic ovary syndrome  
**PCOSQ-50:** Health-Related Quality of Life Questionnaire for Polycystic Ovary Syndrome  
**RIES:** Research Institute for Endocrine Studies  
**SHBG:** sex hormone-binding globulin  
**TC:** total cholesterol  
**TLGS:** Tehran Lipid and Glucose Study  
**TG:** triglycerides  
**tT:** total testosterone

*Edited by G Eysenbach; submitted 02.08.17; peer-reviewed by S Behboudi Gandevani, M Rahmati; comments to author 23.08.17; revised version received 27.08.17; accepted 28.08.17; published 29.09.17*

Please cite as:

Amiri M, Nahidi F, Khalili D, Bidhendi-Yarandi R, Ramezani Tehrani F

*Comparing the Effects of Oral Contraceptives Containing Levonorgestrel With Products Containing Antiandrogenic Progestins on Clinical, Hormonal, and Metabolic Parameters and Quality of Life in Women With Polycystic Ovary Syndrome: Crossover Randomized Controlled Trial Protocol*

*JMIR Res Protoc* 2017;6(9):e191

URL: <http://www.researchprotocols.org/2017/9/e191/>

doi: [10.2196/resprot.8631](https://doi.org/10.2196/resprot.8631)

PMID: [28963092](https://pubmed.ncbi.nlm.nih.gov/28963092/)

©Mina Amiri, Fatemeh Nahidi, Davood Khalili, Razieh Bidhendi-Yarandi, Fahimeh Ramezani Tehrani. Originally published in JMIR Research Protocols (<http://www.researchprotocols.org>), 29.09.2017. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on <http://www.researchprotocols.org>, as well as this copyright and license information must be included.